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Venous malformations (VMs) are common vascular anomalies
affecting 1–4% of the population.1,2 These slow-flowing,
abnormally shaped and dilated veins3 can be superficial or
deep, localized or diffuse, and may occur in multiple areas.4
Histologically, VMs appear irregular with a flattened endothe-
lium and a thin basement membrane.1,2 All VMs are present
at birth, but often manifest clinically between infancy and
early adulthood. VMs grow as children develop, and are asso-
ciated with a wide range of symptoms based on their localiza-
tion and size. Most patients experience localized intravascular
coagulopathy that may lead to thrombosis and pain. Symp-
toms can be exacerbated by trauma or altered hormonal states
(puberty, pregnancy).2,5 In larger lesions, the associated
thrombophilic profile of VMs also predisposes patients to deep
venous thrombosis and pulmonary embolism. Management of
VMs includes pressure garments, pain medication and prophy-
lactic heparin during states of increased risk for thrombosis
(pregnancy, prolonged bed rests, surgery). Treatments are
indicated if a lesion causes severe pain, functional impairment
or aesthetic concerns, and include intervention radiology with
sclerotherapy or surgical resection. Importantly, surgical resec-
tion is contraindicated if VMs interact with critical neuro-
vascular structures.
The efficacy of sclerotherapy depends on the sclerosant
used.2 Most sclerosants used for VMs (ethanol, or surfac-
tants such as sodium tetradecylsulfate or polidocanol) trigger
necrosis-mediated vessel destruction.2 Ethanol is the most
efficient agent but also the most toxic. Side-effects of sclero-
therapy, which include skin necrosis and nerve injury at the
site of injection, can affect up to 30% of treated patients.2
With the choice of sclerosant being the most important var-
iable for complications, research aimed at identifying effi-
cient therapies with fewer side-effects is of great clinical
interest.
In this issue of the British Journal of Dermatology, Ren et al.
sought to gain insight into the pathology of VMs by analysing
the expression pattern of CCN proteins in human VM sam-
ples.6 CCNs form a family of six proteins named after their
first three members [Cyr61 is CCN1; connective tissue growth
factor is CCN2; and nephroblastoma overexpressed (Nov) is
CCN3]. CCNs are multimodular, matricellular proteins
involved in a plethora of biological functions encompassing
embryogenesis, inflammation, fibrosis and tumorigenesis.7,8
Ren et al. found that CCN2 levels are reduced in VMs com-
pared with normal skin blood vessels. The authors also show
colocalization of CCN2 with the profibrotic transforming
growth factor (TGF)b in human cutaneous blood vessels, and
underscore a significant correlation between reduced CCN2
protein and reduction of TGFb and perivascular a-smooth
muscle actin levels in VMs. These results, suggestive of an
association between the TGFb/CCN2 pathway and vascular
integrity in human skin, are consistent with previous work
identifying CCN2 as a critical endothelial organizer, a media-
tor of vascular basement membrane production in mice,9 and
a downstream effector of TGFb-mediated extracellular matrix
production.10 Ren et al. further demonstrate that TGFb or
CCN2 stimulates extracellular matrix production by endothelial
cells in vitro, and that these effects can be mimicked by the
sclerotic agent bleomycin A5. Interestingly, recent clinical
studies have demonstrated the efficacy of bleomycin for scle-
rotherapy of VMs11,12 and other vascular anomalies.13 In all,
the study by Ren et al. proposes an underlying mechanism for
loss of blood vessel integrity in VMs, and suggests that thera-
peutic strategies aimed at restoring CCN2 and/or extracellular
matrix production in VMs should receive careful consider-
ation.
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In their original article in the current issue of BJD, Moertz
et al.1 present findings from a 15-year follow-up of The
Odense Adolescence Cohort Study on Atopic Diseases and Der-
matitis (TOACS), in which 1271 adolescents with a mean age
of 14 years had originally been enrolled. A response rate of
75% was achieved in the questionnaire follow-up. Keeping
loss to follow-up low is important for any prospective cohort
study to avoid the reporting of biased results. The study is
important because it is the first to report on the epidemiology
of hand eczema (HE) from adolescence to adulthood in an
unselected population.
The first aim of the study was to estimate the incidence of
HE from adolescence to adulthood, i.e. the number of newly
occurring cases of HE in the observation period. An incidence
rate of 88 per 1000 persons per year was estimated. The pe-
riod from adolescence to adulthood is critical for the develop-
ment of HE, and it is this period in which occupational choices
are made and some young adults will choose occupations car-
rying an elevated risk of developing HE. Previous studies
reporting incidence data have either been limited to adult pop-
ulations2,3 or have followed up selected populations of adoles-
cents such as car industry apprentices.4 The second aim was to
estimate HE prevalence, which is important in order to under-
stand the population burdened with the disease. The point, 1-
year-period and lifetime prevalence rates were estimated at
71%, 144% and 230%, respectively. A review of epidemio-
logical studies on HE, including seven population-based stud-
ies, reported lower estimates for incidence (55 cases per 1000
person-years) and point, 1-year-period and lifetime prevalence
rates (40%, 10% and 15%, respectively).5 This reflects the
younger age group investigated in TOACS and demonstrates
that the onset and burden of HE are particularly high in adoles-
cents and young adults. Both the TOACS follow-up and the
review found incidence and prevalence estimates to be substan-
tially higher in women than men.
The third aim of Moertz et al. was to investigate risk factors
for HE in the past year in the young adults who were followed
up, applying logistic regression modelling. Studying risk factors
for HE is important in order to identify those modifiable factors
that act in concert with constitutional factors, but are therefore
amenable to prevention and/or early treatment. The significant
positive associations of childhood atopic dermatitis with HE in
adolescence3,6 and taking care of small children with HE,7 as
well as the lack of association of nickel sensitization and HE,6,8
have been previously reported. The lack of association of HE
with smoking seems to contradict previous findings,9,10 but
the effects of smoking seem to depend on exposure level and
may also be restricted to certain subtypes of HE. Although the
clinical examination included in the study by Moertz et al.
showed that most cases of HE that were examined were actu-
ally mild, it is striking that the chances of sick leave, disability
pension or rehabilitation were found to be almost threefold
increased with HE, pointing to the potentially severe conse-
quences of HE already in young adults.
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